Sarcoidosis following alemtuzumab treatment for multiple sclerosis
View / Open Files
Publication Date
2018-11Journal Title
Multiple Sclerosis
ISSN
1477-0970
Publisher
SAGE Publications
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Jones, J., Willis, M., & Coles, A. (2018). Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis https://doi.org/10.1177/1352458518790391
Abstract
Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report 3 (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.
Keywords
Multiple sclerosis, alemtuzumab, Adult, Alemtuzumab, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, Female, Humans, Male, Multiple Sclerosis, Retrospective Studies, Sarcoidosis, Treatment Outcome, Young Adult
Sponsorship
Medical Research Council (G1100114)
Wellcome Trust (105924/Z/14/Z)
Identifiers
External DOI: https://doi.org/10.1177/1352458518790391
This record's URL: https://www.repository.cam.ac.uk/handle/1810/285728
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk